VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | ELEANOR: real-world use of neratinib in HER2+, early breast cancer

Nadia Harbeck, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the ongoing ELEANOR study, a multi-national, prospective, non-interventional study (NIS) in patients with HER2-positive early breast cancer observcing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Nadia Harbeck, MD, PhD, has received honoraria for lectures and/or consulting: Amgen, Astra Zeneca, Daiichi-Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen
Institution: Clinical phase II-IV trials
Other: Co-Director West German Study Group (WSG)

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter